AtriCure Q1 2026: Solid Growth & Innovation

AtriCures Q1 2026 results show strong growth, with worldwide revenue up 14.3% to $141.2M, driven by U.S. sales and new products like the cryoSPHERE MAX probe. The BoxX-NoAF trial is enrolling patients ahead of schedule, aiming to reduce postoperative atrial fibrillation. Surgeons are embracing new tools like the FLEX-Mini device, which could significantly impact the $2B annual U.S. healthcare cost. AtriCure maintains full-year revenue guidance and looks to international growth with new launches and trial progress. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/12f3146efe073c38